Rumst

This research aims to collect liquid biopsy samples from patients with neuroendocrine neoplasms NEN to build a large biobank for analyzing circulating cell-free DNA ccfDNA. The study focuses on validating new techniques to detect and measure circular tumor DNA ctDNA in blood samples and monitoring tumor DNA levels over time, linking these findings to disease progression. Patients included have measurable tumors, with a subgroup receiving more intensive monitoring if they start first-line systemic treatments for specific NEN types. Participants are divided into two groups the Regular Sampling Group, including all NEN patients with measurable tumor burden, and the Intensive Sampling Group, which includes those starting first-line systemic treatments for pancreatic, colorectal, or small intestinal neuroendocrine tumors or carcinomas. Blood samples are collected at multiple timepoints, with up to four additional tubes taken each time for ccfDNA and RNA analysis. Patients in the Intensive Sampling Group switch back to Regular Sampling after progression or three years. During the study, participants provide periodic blood samples for ccfDNA and RNA extraction, with data collected over up to five years. Researchers assess new ccfDNA analysis methods and track tumor DNA levels using shallow whole genome sequencing and methylation-sensitive assays. They correlate tumor DNA quantities with disease progression based on imaging criteria. Samples from all participants are stored for future research. The study involves regular follow-up and monitoring of tumor burden and treatment response.

Researchers are evaluating the effects of continuing versus stopping somatostatin analog SSA treatment in patients with advanced, non-functional gastroenteropancreatic GEP neuroendocrine tumors NET who have progressive disease despite first-line SSA therapy. This Phase 4, multi-national, open-label, randomized, controlled trial divides eligible patients into two groups based on their second-line therapy choice peptide receptor radionuclide therapy PRRT or targeted therapy. The study aims to understand the impact of continuing SSA treatment alongside second-line therapies, stratifying patients by tumor grade and study site.

Neuroendocrine tumors NET are rare and challenging to diagnose and treat, requiring specialized care. This study is focused on patients with NET or those suspected of having NET within a hospital network called NETwerk, involving several hospitals working together to improve patient care. The main goal is to understand and improve the quality of life and quality of care for these patients over time. Participants in this study will be asked to complete three questionnaires the EORTC QLQ-C30 and EORTC QLQ-GI.NET21, which assess quality of life, and a satisfaction survey about their care experience. These questionnaires are completed at home every six months, with the satisfaction survey completed at the start of the study. This process continues over a five-year period. During the study, patients will regularly provide information through these questionnaires to help researchers evaluate their quality of life and satisfaction with care. The primary outcomes measured are the quality of life scores from the QLQ-C30 and QLQ-GI.NET21 questionnaires over five years, while the satisfaction survey evaluates quality of care. This long-term follow-up helps monitor patients experiences and care outcomes within the NETwerk.

Researchers are studying how extracorporeal shock wave therapy ESWT, a non-invasive mechanical treatment, affects postsurgical scars, especially those after abdominoplasty and breast reduction. Scars from deep injuries can cause pain, itching, and aesthetic concerns. The study aims to understand how mechanical forces influence scar healing on a cellular level and to determine the best ESWT treatment settings during different wound healing phases. The study involves applying focused ESWT to scarred areas in three intervention groups, each receiving 10 treatments once a week. Different energy levels, frequencies, and intensities of ESWT will be tested to see how they affect scar tissue and cellular pathways. There will also be control groups that do not receive ESWT. Biopsies from abdominoplasty scars will be collected before and after treatment to examine changes in scar tissue at various healing stages. Participants will undergo several assessments including biopsies and non-invasive scar evaluations measuring color, thickness, elasticity, and patient-reported outcomes. These evaluations take place at baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year. The study will track changes in molecular markers related to scarring and how they relate to physical scar characteristics. Safety and quality of life will also be monitored throughout the study period.